Bio-Techne(US:TECH) Prnewswireยท2025-08-05 20:30Core Viewpoint - Bio-Techne Corporation has entered into an agreement for Mdxhealth SA to acquire its Exosome Diagnostics Inc. business, which includes the ExoDx Prostate (EPI) test and a CLIA-certified clinical laboratory, while Bio-Techne retains access to the proprietary exosome-based technology for future kit development [1][2]. Group 1: Transaction Details - Mdxhealth is seen as an ideal acquirer for the ExoDx Prostate test and laboratory, enhancing its leadership in urology and prostate cancer diagnostics [2]. - Bio-Techne will receive $5 million in MDXH stock along with future considerations as part of the transaction, expected to close in the first quarter of Bio-Techne's fiscal 2026 [2]. Group 2: Strategic Implications - The acquisition allows Bio-Techne to focus on developing high-value, high-margin products for life science research and clinical diagnostics, thereby improving its operating margin profile [2]. - Mdxhealth views the ExoDx Prostate test as a strategic fit that will help men make informed decisions regarding prostate biopsies, building on Bio-Techne's success in delivering this information [2]. Group 3: Company Background - Bio-Techne Corporation is a global life sciences company with approximately $1.2 billion in net sales for fiscal 2024 and over 3,000 employees worldwide, providing innovative tools and bioactive reagents for research and clinical diagnostics [6]. - Mdxhealth specializes in precision diagnostics for cancer, utilizing proprietary genetic and molecular technologies to assist in the diagnosis and prognosis of urologic cancers [7].